Consist of Infection and Immune-Related Diseases experts

Innovative new drugs development company

that develops immunosuppressants,
and develops antibiotics against super bacteria to combat sepsis

A global biopharmaceutical company
With DanDi Bioscience

DANDI BIOSCIENCE'SINNOVATIVE LIFE SCIENCE AND MEDICINE CORE TECHNOLOGY

Sepsis Therapeutics
Antibiotic against Super Bacteria
Blood Purification Module
LPS Removal Kit
IMMUNO-SUPPRESSOR TARGET DRUG DELIVERY PLATFORM
Vaccine Adjuvants
Highly Pathogenic Influenza Therapeutics
Rheumatoid Arthritis therapeutics
Hangover Recovery
DD-S052, three-concepts based candidate for sepsis treatment

DD-S052 is an innovative candidate that exterminates germs and eliminates endotoxins.

Antibiotics that treat sepsis are designed to exterminates the causative pathogens, however, the removal of endotoxins released during the apoptosis of pathogens is overlooked. Especially, the cytokine storm phenomenon, that exacerbate the morbidity of sepsis by causing necrosis in several tissues.

Multi
targeting therapeuticsDD-S052
  • Bacteria killing
    (Super Bacteria)

  • LPS
    elimination

  • Synergistic
    (Bactericidal effect)

  • Antibiotic against
    Super bacteria

  • LPS Removal Kit

    Blood Purification
    Module

  • Synergistic effect by
    co-administration
    with existing antibiotics (easier access to clinical trials)

DanDi Bioscience is

committed to protecting the health
and
well-being of more people
with the best experts.

DanDi Bioscience Co., Ltd.
  • Address

    (Zipcode:05029) #304, Biomedical Science and Technology Building, Konkuk Univ., 120, Neungdong-ro, Gwangjin-gu, Seoul, Republic of Korea

  • Fax

    070-8280-0378

  • E-mail

    dandibio@dandibio.com